Single User License
INR 202133
Site License
INR 404265
Corporate User License
INR 606398

Service Tax Additional

select a format
Price

Single User License
USD 2995
Site License
USD 5990
Corporate User License
USD 8985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook


  Request for Sample Report

Executive Summary

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook GBI Research's latest report, "Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook" discusses all gene therapies under the broad criteria of genetic material introduced to the cell for a therapeutic purpose. It includes not only the insertion of a gene into the cell for expression, but also gene silencing with RNA interference (RNAi) and antisense RNA, aptamers (DNA or RNA polymers which bind to a protein target), and oncolytic viruses. Gene therapies have been in development in humans for 25 years, and a number of products have begun to enter the pharmaceutical market. However, due to various challenges and clinical trial setbacks, progress in developing this technology and achieving suitability for commercial usage has been slow. Gene therapies only account for a marginal market share and many efficacy and safety concerns remain unaddressed. However, the pipeline is robust; 906 pipeline gene therapies are currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. However, there are currently 23 gene therapy programs in Phase III development and two at the Pre-registration stage. This indicates that although gene therapies are beginning to reach the market after two decades of research in humans, the majority remain in relatively early development. This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of Gene Therapy, and assesses key developments in delivery vector technology, and challenges and advances associated with the production of such vectors. Scope Despite 25 years of clinical research, only a few gene therapies of all types have reached the market globally, and none have achieved strong clinical or commercial success -Why do gene therapies still occupy only a minimal market share in their respective indications? -What can be learned from the gene therapies that have already reached the market? A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies -What are the relative advantages and disadvantages of each vector type and which hold the most promise? -What proportion of the overall gene therapy R&D pipeline is occupied by each vector type? The current pipeline for gene therapies is diverse in terms of the approaches and vectors covered; 50% are gene silencing therapies, while 31% involve the insertion of a functional gene -In which therapy areas is there the highest level of R&D activity for gene therapies? -At which stage of development does the majority of pipeline gene therapies reside? -What is the proportion of the pipeline occupied by each intervention and vector type overall? A number of companies are currently actively developing pipeline gene therapies, including private, public and institutional enterprises -How do gene therapies fit into the overall portfolios of these companies? -What is the level of involvement in gene therapy research from the top 20 Big Pharma companies? Reasons To Buy This report will allow you to Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products, comprising Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and Neovasculgen. Assess the pipeline for gene therapies split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, infectious diseases, central nervous system disorders, and genetic disorders. Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline. Understand the level of involvement on the part of big pharma companies, and the extent to which gene therapies fit into the overall portfolios of companies in this field. Additionally, a highly granular breakdown of companies developing multiple gene therapies is provided.

Gene Therapy Overview Types of Gene Therapy Types of Intervention Types of Vector Currently Approved Gene Therapies Glybera (alipogene tiparvovec) Kynamro (mipomersen) Macugen (pegaptanib) Vitravene (fomivirsen) Gendicine (rAd-p53) Oncorine (rAd5-H101) Neovasculgen (Pl-VEGF165) Gene Therapy Production Strategies Production of Viral Vectors Case Study: Challenges in the Manufacture of AAV Vectors Challenges to Gene Therapy Development Gene Therapy Pipeline Gene Therapy Pipeline by Therapy Area and Stage of Development Gene Therapy Pipeline by Intervention and Vector Type Company Positioning Companies by Therapy Area Companies by Stage of Development Companies by Intervention Type Companies by Vector Type Conclusion Appendix References About GBI Research

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Gene Therapies


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com